[开放获取]    中国药疹诊疗指南（2026版）

doi:10.35541/cjd.20250504

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (9): 811-826.doi: 10.35541/cjd.20250504

• 指南与共识·免疫介导炎症性皮肤病 • 上一篇下一篇

[开放获取] 中国药疹诊疗指南（2026版）

中华医学会皮肤性病学分会中华医学会变态反应学分会中国麻风防治协会

中华医学会皮肤性病学分会中华医学会变态反应学分会中国麻风防治协会

收稿日期:2025-09-18 修回日期:2026-07-11 发布日期:2026-09-03
通讯作者: 骆肖群；张福仁 E-mail:luoxiaoqun913@126.com; zhangfuren@hotmail.com
基金资助:
国家自然科学基金（82230107，82173422）；2021年医疗服务与保障能力提升项目（国家临床重点专科建设项目）（303029401）；山东省重点研发计划项目（2025CXPTWZ002）

Chinese guideline for the diagnosis and treatment of drug eruptions （2026 edition）

Chinese Society of Dermatology; Chinese Society of Allergy; China Leprosy Association

Chinese Society of Dermatology; Chinese Society of Allergy; China Leprosy Association

Received:2025-09-18 Revised:2026-07-11 Published:2026-09-03
Contact: Luo Xiaoqun; Zhang Furen E-mail:luoxiaoqun913@126.com; zhangfuren@hotmail.com
Supported by:
National Natural Science Foundation of China （82230107,82173422）; 2021 Medical Service and Security Capacity Improvement Project （National Clinical Key Specialty Construction Project）（303029401）; Key Research and Development Program of Shandong Province （2025CXPTWZ002）

摘要/Abstract

摘要： 【摘要】药疹（皮肤药物不良反应）指药物通过口服、注射、吸入等途径进入人体后引起的皮肤、黏膜炎症性皮损，严重者可同时累及皮肤以外的器官乃至引起死亡。近年来，药疹的诊疗领域进展迅速。国内现有药疹相关的共识或指南对药疹的系统性、循证化临床诊疗规范缺乏统一标准。为规范药疹的诊疗，中华医学会皮肤性病学分会、中华医学会变态反应学分会、中国麻风防治协会组织56名专家，基于最新文献，依据世界卫生组织指南制订手册，参考推荐的分级、评估、制订与评价等方法制订了本指南。本指南更新、更全面地归纳了药疹的诊断、治疗和预防管理，旨在帮助临床医生提升识别药疹、规范治疗和科学防控的能力。

关键词: 药疹, 药物相关性副作用和不良反应, 重症药疹, 诊疗指南

Abstract: 【Abstract】 Drug eruptions, also referred to as cutaneous adverse drug reactions, are inflammatory skin and mucosal lesions that occur following drug exposure via oral, injectable, inhalational, or other routes. In severe cases, extracutaneous organ involvement may occur and may even lead to death. In recent years, substantial progress has been made in the diagnosis and treatment of drug eruptions. However, existing consensus statements and guidelines in China lack unified standards for systematic, evidence-based clinical management of drug eruptions. To standardize the diagnosis and treatment of drug eruptions, the Chinese Society of Dermatology, the Chinese Society of Allergy, and the China Leprosy Association convened 56 experts to develop this guideline. Based on the latest literature, the guideline was formulated in accordance with the World Health Organization Handbook for Guideline Development and the Grading of Recommendations Assessment, Development, and Evaluation methodology. This guideline provides updated and comprehensive recommendations for the diagnosis, treatment, and preventive management of drug eruptions, with the aim of enhancing clinicians' capacity to recognize drug eruptions, deliver standardized treatment, and implement evidence-based prevention strategies.

Key words: Drug eruptions, Drug-related side effects and adverse reactions, Severe drug eruptions, Diagnostic and treatment guideline

中华医学会皮肤性病学分会中华医学会变态反应学分会中国麻风防治协会. [开放获取] 中国药疹诊疗指南（2026版）[J]. 中华皮肤科杂志, 2026,59(9):811-826. doi:10.35541/cjd.20250504

Chinese Society of Dermatology, Chinese Society of Allergy, China Leprosy Association. Chinese guideline for the diagnosis and treatment of drug eruptions （2026 edition）[J]. Chinese Journal of Dermatology, 2026, 59(9): 811-826.doi:10.35541/cjd.20250504

参考文献 92

［1］	中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识［J］. 中华皮肤科杂志, 2021,54（5）:376⁃381. DOI: 10.35541/cjd.20201177.
［2］	中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 药疹基层诊疗指南（2022年）［J］. 中华全科医师杂志, 2022,21（9）:804⁃813. DOI: 10.3760/cma.j.cn114798⁃20220215⁃00101.
［3］	Brockow K, Ardern⁃Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity［J］. Allergy, 2019,74（1）:14⁃27. DOI: 10.1111/all.13562.
［4］	Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update［J］. J Allergy Clin Immunol, 2022,150（6）:1333⁃1393. DOI: 10.1016/j.jaci.2022.08.028.
［5］	Barbaud A, Garvey LH, Torres M, et al. EAACI/ENDA position paper on drug provocation testing［J］. Allergy, 2024,79（3）:565⁃579. DOI: 10.1111/all.15996.
［6］	Jiang M, Yang F, Zhang L, et al. Unique motif shared by HLA⁃B59:01 and HLA⁃B55:02 is associated with methazolamide⁃induced Stevens⁃Johnson syndrome and toxic epidermal necrolysis in Han Chinese［J］. J Eur Acad Dermatol Venereol, 2022,36（6）:873⁃880. DOI: 10.1111/jdv.17980.
［7］	Jiang H, Wang CW, Wang Z, et al. Functional and structural characteristics of HLA⁃B*13:01⁃mediated specific T cells reaction in dapsone⁃induced drug hypersensitivity［J］. J Biomed Sci, 2022,29（1）:58. DOI: 10.1186/s12929⁃022⁃00845⁃8.
［8］	Cadot R, Gery P, Lenief V, et al. Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology［J］. Allergy, 2025,80（1）:47⁃62. DOI: 10.1111/all.16316.
［9］	Zhang J, Lei Z, Xu C, et al. Current perspectives on severe drug eruption［J］. Clin Rev Allergy Immunol, 2021,61（3）:282⁃298. DOI: 10.1007/s12016⁃021⁃08859⁃0.
［10］	Sun LL, Huai PC, Wang ZZ, et al. TSC22 domain family member 3 links natural killer cells to CD8+ T cell⁃mediated drug hypersensitivity［J］. Signal Transduct Target Ther, 2025,10（1）:196. DOI: 10.1038/s41392⁃025⁃02300⁃0.
［11］	Li L, Naisbitt DJ, Sun Y, et al. Pathomechanism of adverse reactions to biological treatment of inflammatory skin conditions［J］. Clin Exp Allergy, 2024,54（12）:973⁃983. DOI: 10.1111/cea.14583.
［12］	Bavbek S, Pagani M, Alvarez⁃Cuesta E, et al. Hypersensitivity reactions to biologicals: an EAACI position paper［J］. Allergy, 2022,77（1）:39⁃54. DOI: 10.1111/all.14984.
［13］	Maronese CA, Valenti M, Moltrasio C, et al. Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options［J］. J Invest Dermatol, 2024,144（11）:2364⁃2376. DOI: 10.1016/j.jid.2024.05.015.
［14］	Shah H, Parisi R, Mukherjee E, et al. Update on Stevens⁃Johnson syndrome and toxic epidermal necrolysis: diagnosis and management［J］. Am J Clin Dermatol, 2024,25（6）:891⁃908. DOI: 10.1007/s40257⁃024⁃00889⁃6.
［15］	Mizukawa Y, Shiohara T. Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025［J］. Allergol Int, 2025,74（3）:372⁃379. DOI: 10.1016/j.alit.2025.03.007.
［16］	Duong TA, Valeyrie⁃Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs［J］. Lancet, 2017,390（10106）:1996⁃2011. DOI: 10.1016/S0140⁃6736（16）30378⁃6.
［17］	中国医学装备协会皮肤病与皮肤美容分会, 中国临床肿瘤学会患者教育专家委员会. 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识（2026版）［J］. 中华皮肤科杂志, 2026,59（4）:304⁃319. DOI: 10.35541/cjd.20250344.
［18］	上海市医学会皮肤性病学分会, 上海市医学会肿瘤靶分子专科分会. 抗肿瘤药物相关皮肤不良反应管理专家共识［J］. 中华皮肤科杂志, 2023,56（10）:907⁃919. DOI: 10.35541/cjd. 20230084.
［19］	Shah H, Parisi R, Mukherjee E, et al. Update on Stevens⁃Johnson syndrome and toxic epidermal necrolysis: diagnosis and management［J］. Am J Clin Dermatol, 2024,25（6）:891⁃908. DOI: 10.1007/s40257⁃024⁃00889⁃6.
［20］	Parvathaneni A, Benchetrit L, Metcalfe D, et al. Attribution of causality in Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. Ocul Surf, 2025,38:104⁃112. DOI: 10.1016/j.jtos.2025.06.004.
［21］	Brüggen MC, Walsh S, Ameri MM, et al. Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a delphi⁃based international consensus［J］. JAMA Dermatol, 2024,160（1）:37⁃44. DOI: 10.1001/jamadermatol. 2023.4450.
［22］	Kardaun SH, Sekula P, Valeyrie⁃Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms （DRESS）: an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study［J］. Br J Dermatol, 2013,169（5）:1071⁃1080. DOI: 10.1111/bjd.12501.
［23］	Mizukawa Y, Hirahara K, Kano Y, et al. Drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease［J］. J Am Acad Dermatol, 2019,80（3）:670⁃678.e2. DOI: 10.1016/j.jaad.2018.08.052.
［24］	卫生健康委员会. β⁃内酰胺类抗菌药物皮肤试验指导原则（2021年版）［EB/OL］. （2021⁃04⁃13）［2026⁃08⁃08］. https://www.nhc.gov.cn/wjw/c100175/202104/adf092f23a9e468c9117c896e27f7b62.shtml.
［25］	Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions［J］. Br J Dermatol, 2013,168（3）:555⁃562. DOI: 10.1111/bjd.12125.
［26］	Banerji A, Solensky R, Phillips EJ, et al. Drug allergy practice parameter updates to incorporate into your clinical practice［J］. J Allergy Clin Immunol Pract, 2023,11（2）:356⁃368. DOI: 10. 1016/j.jaip.2022.12.002.
［27］	中华预防医学会过敏病预防与控制专业委员会预防食物药物过敏学组. 药物激发试验专家共识［J］. 中华预防医学杂志, 2020,54（10）:1060⁃1068. DOI: 10.3760/cma.j.cn112150⁃20200711⁃00997.
［28］	You J, Sun L, Zhao Q, et al. Dynamic cytokine profiles combined with enzyme⁃linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome［J］. J Am Acad Dermatol, 2021,84（3）:814⁃816. DOI: 10.1016/j.jaad.2020.06.032.
［29］	Xiong H, Chen S, Luo X. Salazosulphapyridine⁃related Stevens⁃Johnson syndrome caused by sulphapyridine and confirmed by enzyme⁃linked immunospot assay［J］. J Crohns Colitis, 2018,12（3）:381⁃382. DOI: 10.1093/ecco⁃jcc/jjx148.
［30］	Yue Z, Sun Y, Wang C, et al. Amino acid variants of HLA⁃DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA⁃B*13:01［J］. J Invest Dermatol, 2018,138（5）:1101⁃1106. DOI: 10.1016/j.jid.2017.11.027.
［31］	Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. DOI: 10.1056/NEJMoa1213096.
［32］	Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA⁃B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy［J］. JAMA Dermatol, 2019,155（6）:666⁃672. DOI: 10.1001/jamadermatol.2018.5360.
［33］	Swen JJ, van der Wouden CH, Manson LE, et al. A 12⁃gene pharmacogenetic panel to prevent adverse drug reactions: an open⁃label, multicentre, controlled, cluster⁃randomised crossover implementation study［J］. Lancet, 2023,401（10374）:347⁃356. DOI: 10.1016/S0140⁃6736（22）01841⁃4.
［34］	Thorel D, Ingen⁃Housz⁃Oro S, Royer G, et al. Management of ocular involvement in the acute phase of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement［J］. Orphanet J Rare Dis, 2020,15（1）:259. DOI: 10.1186/s13023⁃020⁃01538⁃x.
［35］	Tóth G, Lukács A, Schirra F, et al. Ophthalmic aspects of stevens⁃johnson syndrome and toxic epidermal necrolysis: a narrative review［J］. Ophthalmol Ther, 2023,12（4）:1795⁃1811. DOI: 10. 1007/s40123⁃023⁃00725⁃w.
［36］	Mortensen XM, Shenkute NT, Zhang AY, et al. Clinical outcome of amniotic membrane transplant in ocular Stevens⁃Johnson syndrome/toxic epidermal necrolysis at a major burn unit［J］. Am J Ophthalmol, 2023,256:80⁃89. DOI: 10.1016/j.ajo.2023. 07.026.
［37］	Gregory DG. Treatment of acute Stevens⁃Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases［J］. Ophthalmology, 2011,118（5）:908⁃914. DOI: 10.1016/j.ophtha.2011.01.046.
［38］	Shiohara T, Mizukawa Y. Drug⁃induced hypersensitivity syndrome （DiHS）/drug reaction with eosinophilia and systemic symptoms （DRESS）: an update in 2019［J］. Allergol Int, 2019,68（3）:301⁃308. DOI: 10.1016/j.alit.2019.03.006.
［39］	Pichler WJ, Brüggen MC. Viral infections and drug hypersensitivity［J］. Allergy, 2023,78（1）:60⁃70. DOI: 10.1111/all.15558.
［40］	Ishida T, Kano Y, Mizukawa Y, et al. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome［J］. Allergy, 2014,69（6）:798⁃805. DOI: 10.1111/all.12410.
［41］	Yamane Y, Matsukura S, Watanabe Y, et al. Retrospective analysis of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients⁃⁃treatment and outcome［J］. Allergol Int, 2016,65（1）:74⁃81. DOI: 10.1016/j.alit.2015.09.001.
［42］	Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2017,153（6）:514⁃522. DOI: 10.1001/jamadermatol.2016.5668.
［43］	Hama N, Aoki S, Chen CB, et al. Recent progress in Stevens⁃Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment［J］. Br J Dermatol, 2024,192（1）:9⁃18. DOI: 10.1093/bjd/ljae321.
［44］	Hsieh MH, Watanabe T, Aihara M. Recent dermatological treatments for Stevens⁃Johnson syndrome and toxic epidermal necrolysis in Japan［J］. Front Med （Lausanne）, 2021,8:636924. DOI: 10.3389/fmed.2021.636924.
［45］	Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens⁃Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine［J］. J Am Acad Dermatol, 2014,71（5）:941⁃947. DOI: 10.1016/j.jaad.2014.07.016.
［46］	González⁃Herrada C, Rodríguez⁃Martín S, Cachafeiro L, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches［J］. J Invest Dermatol, 2017,137（10）:2092⁃2100. DOI: 10.1016/j.jid.2017.05.022.
［47］	Valeyrie⁃Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Br J Dermatol, 2010,163（4）:847⁃853. DOI: 10.1111/j.1365⁃2133.2010.09863.x.
［48］	Gong T, Zhang P, Ruan SF, et al. APOA4 as a novel predictor of prognosis in Stevens⁃Johnson syndrome/toxic epidermal necrolysis: a proteomics analysis from two prospective cohorts［J］. J Am Acad Dermatol, 2023,89（1）:45⁃52. DOI: 10.1016/j.jaad.2023. 02.058.
［49］	Chen CB, Hung SI, Chang JW, et al. Immune checkpoint inhibitor⁃induced severe epidermal necrolysis mediated by macrophage⁃derived CXCL10 and abated by TNF blockade［J］. Nat Commun, 2024,15（1）:10733. DOI: 10.1038/s41467⁃024⁃54180⁃7.
［50］	Olsson⁃Brown A, Yip V, Ogiji ED, et al. TNF⁃α⁃mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. J Invest Dermatol, 2023,143（6）:1023⁃1030.e7. DOI: 10.1016/j.jid.2022.11.024.
［51］	Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. DOI: 10.1172/JCI93349.
［52］	Ao S, Gao X, Zhan J, et al. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis in a cohort of patients［J］. J Am Acad Dermatol, 2022,86（6）:1236⁃1245. DOI: 10.1016/j.jaad.2022.01.039.
［53］	Zhang J, Lu CW, Chen CB, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for stevens⁃johnson syndrome and toxic epidermal necrolysis: a multicenter observational study［J］. J Allergy Clin Immunol Pract, 2022,10（5）:1295⁃1304.e6. DOI: 10.1016/j.jaip.2022.01.038.
［54］	Sun L, Zhao Q, Ao S, et al. Feedback regulation of VISTA and Treg by TNF⁃α controls T cell responses in drug allergy［J］. Allergy, 2025,80（5）:1400⁃1416. DOI: 10.1111/all.16393.
［55］	Cao J, Zhang X, Xing X, et al. Biologic TNF⁃α inhibitors for Stevens⁃Johnson syndrome, toxic epidermal necrolysis, and ten⁃sjs overlap: a study⁃level and patient⁃level meta⁃analysis［J］. Dermatol Ther （Heidelb）, 2023,13（6）:1305⁃1327. DOI: 10. 1007/s13555⁃023⁃00928⁃w.
［56］	Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（2）:390⁃397. DOI: 10.1016/j.jaad.2020. 08.122.
［57］	Koh HK, Fook⁃Chong S, Lee HY. Assessment and comparison of performance of ABCD⁃10 and SCORTEN in prognostication of epidermal necrolysis［J］. JAMA Dermatol, 2020,156（12）:1294⁃1299. DOI: 10.1001/jamadermatol.2020.3654.
［58］	Torres⁃Navarro I, Briz⁃Redón Á, Botella⁃Estrada R. Systemic therapies for Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a SCORTEN⁃based systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2021,35（1）:159⁃171. DOI: 10.1111/jdv.16685.
［59］	Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens⁃Johnson syndrome （SJS）, toxic epidermal necrolysis （TEN）, and SJS/TEN overlap syndrome［J］. Cochrane Database Syst Rev, 2022,3:CD013130. DOI: 10.1002/14651858.CD013130.pub2.
［60］	Miyamoto Y, Ohbe H, Kumazawa R, et al. Evaluation of plasmapheresis vs immunoglobulin as first treatment after ineffective systemic corticosteroid therapy for patients with Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. JAMA Dermatol, 2023,159（5）:481⁃487. DOI: 10.1001/jamadermatol.2023.0035.
［61］	Nordmann TM, Anderton H, Hasegawa A, et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease［J］. Nature, 2024,635（8040）:1001⁃1009. DOI: 10.1038/s41586⁃024⁃08061⁃0.
［62］	Uzun R, Yalcin AD, Celik B, et al. Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab （anti⁃ige） and pulse prednisolone［J］. Am J Case Rep, 2016,17:666⁃671. DOI: 10.12659/ajcr.899823.
［63］	Wei BM, Fox LP, Kaffenberger BH, et al. Drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. PartⅡ diagnosis and management［J］. J Am Acad Dermatol, 2024,90（5）:911⁃926. DOI: 10.1016/j.jaad. 2023.02.073.
［64］	Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions［J］. Nat Rev Dis Primers, 2024,10（1）:30. DOI: 10.1038/s41572⁃024⁃00514⁃0.
［65］	Brin C, Bernigaud C, Hua C, et al. Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms （DRESS）: a monocenter retrospective study of 20 cases［J］. Ann Dermatol Venereol, 2021,148（3）:168⁃171. DOI: 10.1016/j.annder.2021.02.002.
［66］	Hashizume H, Ishikawa Y, Ajima S. Is steroid pulse therapy a suitable treatment for drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms? A systematic review of case reports in patients treated with corticosteroids in Japan［J］. J Dermatol, 2022,49（2）:303⁃307. DOI: 10.1111/1346⁃8138.16230.
［67］	Mizukawa Y, Hama N, Miyagawa F, et al. Drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: predictive score and outcomes［J］. J Allergy Clin Immunol Pract, 2023,11（10）:3169⁃3178. DOI: 10.1016/j.jaip.2023.06.065.
［68］	Wang S, Kang Y, He C, et al. The systemic treatments for drug reaction with eosinophilia and systemic symptoms （DRESS） beyond corticosteroids［J］. World Allergy Organ J, 2024,17（8）:100935. DOI: 10.1016/j.waojou.2024.100935.
［69］	Nguyen E, Yanes D, Imadojemu S, et al. Evaluation of cyclosporine for the treatment of DRESS syndrome［J］. JAMA Dermatol, 2020,156（6）:704⁃706. DOI: 10.1001/jamadermatol. 2020.0048.
［70］	Tan K, Testro A. Cyclosporine as an alternative immunosuppressant for steroid⁃resistant drug reaction with eosinophilia and systemic symptoms （DRESS） syndrome［J］. BMJ Case Rep, 2023,16（3）:250983. DOI: 10.1136/bcr⁃2022⁃250983.
［71］	Shaughnessy KK, Bouchard SM, Mohr MR, et al. Minocycline⁃induced drug reaction with eosinophilia and systemic symptoms （DRESS） syndrome with persistent myocarditis［J］. J Am Acad Dermatol, 2010,62（2）:315⁃318. DOI: 10.1016/j.jaad.2009.05. 046.
［72］	Nie Y, Wang H, Dong X, et al. Case report: drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti⁃interferon⁃γ autoantibody⁃associated immunodeficiency［J］. Front Immunol, 2022,13:969912. DOI: 10.3389/fimmu.2022. 969912.
［73］	Rubin L, Talmon A, Ribak Y, et al. Novel targeted inhibition of the IL⁃5 axis for drug reaction with eosinophilia and systemic symptoms syndrome［J］. Front Immunol, 2023,14:1134178. DOI: 10.3389/fimmu.2023.1134178.
［74］	Khan S. Anti⁃IL⁃5 therapy and DRESS［J］. CMAJ, 2010,182（9）:941. DOI: 10.1503/cmaj.110⁃2054.
［75］	Hijaz B, Nambudiri VE, Imadojemu S. IL⁃5 inhibitor treatment in drug reaction with eosinophilia and systemic symptoms［J］. JAMA Dermatol, 2025,161（6）:661⁃663. DOI: 10.1001/jamadermatol.2025.0441.
［76］	Kim D, Kobayashi T, Voisin B, et al. Targeted therapy guided by single⁃cell transcriptomic analysis in drug⁃induced hypersensitivity syndrome: a case report［J］. Nat Med, 2020,26（2）:236⁃243. DOI: 10.1038/s41591⁃019⁃0733⁃7.
［77］	Chiu TM, Chen CB, Lu CW, et al. CCR8/CCL1 and CXCR3/CXCL10 axis⁃mediated memory T⁃cell activation in patients with recalcitrant drug⁃induced hypersensitivity［J］. Br J Dermatol, 2025,192（2）:293⁃305. DOI: 10.1093/bjd/ljae375.
［78］	Ben Said B, Gerfaud⁃Valentin M, Seve P. Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis［J］. J Allergy Clin Immunol Pract, 2018,6（3）:1048⁃1049. DOI: 10.1016/j.jaip.2017.08.041.
［79］	Valido K, Patel V, Murphy MJ, et al. Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly⁃guided approach［J］. JAAD Case Rep, 2024,48:49⁃53. DOI: 10.1016/j.jdcr.2024. 03.020.
［80］	Ben Said B, Dupire G, Poutrel S, et al. The usefulness of omalizumab in low response to corticosteroids DRESS syndrome: a case series［J］. J Allergy Clin Immunol Pract, 2024,12（1）:236⁃238. DOI: 10.1016/j.jaip.2023.09.036.
［81］	Creadore A, Desai S, Alloo A, et al. Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US［J］. JAMA Dermatol, 2022,158（2）:176⁃183. DOI: 10.1001/jamadermatol.2021.5390.
［82］	Gualtieri B, Solimani F, Hertl M, et al. Interleukin 17 as a therapeutic target of acute generalized exanthematous pustulosis （AGEP）［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2081⁃2084. DOI: 10.1016/j.jaip.2020.01.045.
［83］	Gencoglan G, Tosun M, Aktepe F. The molecular mechanism of etanercept, an anti⁃tumour necrosis factor⁃alpha receptor⁃fusion protein, in the treatment of acute generalized exanthematous pustulosis［J］. J Dermatolog Treat, 2009,20（4）:241⁃245. DOI: 10.1080/09546630802683843.
［84］	Torres⁃Navarro I, Briz⁃Redón Á, Botella⁃Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens⁃Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:2066⁃2077. DOI: 10.1111/jdv.16137.
［85］	Hsieh TS, Chan TC, Cho YT, et al. Comparison of performance of SCORTEN, ABCD⁃10 and Re⁃SCORTEN in a cohort of patients with Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:e514⁃e516. DOI: 10.1111/jdv.18734.
［86］	Hama N, Sunaga Y, Ochiai H, et al. Development and validation of a novel score to predict mortality in Stevens⁃Johnson syndrome and toxic epidermal necrolysis: CRISTEN［J］. J Allergy Clin Immunol Pract, 2023,11（10）:3161⁃3168. DOI: 10. 1016/j.jaip.2023.07.001.
［87］	Waters M, Dobry A, Le ST, et al. Development of a skin⁃directed scoring system for Stevens⁃Johnson syndrome and epidermal necrolysis: a delphi consensus exercise［J］. JAMA Dermatol, 2023,159（7）:772⁃777. DOI: 10.1001/jamadermatol.2023.1347.
［88］	Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol⁃induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin［J］. Ann Rheum Dis, 2015,74（12）:2157⁃2164. DOI: 10.1136/annrheumdis⁃2014⁃205577.
［89］	Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Med, 2008,14（12）:1343⁃1350. DOI: 10.1038/nm.1884.
［90］	Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas⁃L to be related to disease severity［J］. J Allergy Clin Immunol, 2002,109（1）:155⁃161. DOI: 10.1067/mai.2002.120563.
［91］	Yoshioka M, Sawada Y, Nakamura M. Diagnostic tools and biomarkers for severe drug eruptions［J］. Int J Mol Sci, 2021,22（14）:7527. DOI: 10.3390/ijms22147527.
［92］	Mitsui Y, Shinkuma S, Nakamura⁃Nishimura Y, et al. Serum soluble OX40 as a diagnostic and prognostic biomarker for drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms［J］. J Allergy Clin Immunol Pract, 2022,10（2）:558⁃565. DOI: 10.1016/j.jaip.2021.10.042.

[1]	任孙王蓉闵玮. 程序性死亡受体1抑制剂致Stevens-Johnson综合征/中毒性表皮坏死松解症13例临床分析[J]. 中华皮肤科杂志, 2026, 59(9): 888-892.
[2]	赵晴孙乐乐敖穗婷翟于凡刘红张福仁. 以氨苯砜综合征为模型解析药物超敏反应中的免疫失衡[J]. 中华皮肤科杂志, 2026, 59(9): 844-849.
[3]	李燕红姜琨吴卓璇章建兰方美珍刘姝婷王琳琳胡磊周小勇陈柳青陈金波. 程序性死亡受体1抑制剂相关皮肤不良反应18例临床资料分析[J]. 中华皮肤科杂志, 2026, 59(8): 783-787.
[4]	张笑旭罗素菊. 乌帕替尼治疗6例掌跖脓疱病的临床疗效与安全性分析[J]. 中华皮肤科杂志, 2026, 59(5): 459-463.
[5]	中国医学装备协会皮肤病与皮肤美容分会中国临床肿瘤学会患者教育专家委员会. [开放获取] 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(4): 304-319.
[6]	许国康蔡梅. 索立德吉治疗局部晚期基底细胞癌8例临床分析[J]. 中华皮肤科杂志, 2026, 59(2): 166-169.
[7]	张承中岳学状鲁严. 重症药疹住院患者合并下肢深静脉血栓栓塞的影响因素分析[J]. 中华皮肤科杂志, 2026, 59(1): 9-14.
[8]	邱里肖汀. 布鲁顿酪氨酸激酶抑制剂在慢性自发性荨麻疹治疗中的进展[J]. 中华皮肤科杂志, 2025, 58(6): 563-567.
[9]	包诗杰韩梅周小勇. 基于文献回顾的依那西普治疗中毒性表皮坏死松解症疗效影响因素分析[J]. 中华皮肤科杂志, 2025, 58(4): 352-355.
[10]	万勇军杨海晶严翘陈梅王逢源粟倩雅董正邦王飞. 免疫检查点抑制剂相关Stevens-Johnson综合征/中毒性表皮坏死松解症9例临床及预后分析[J]. 中华皮肤科杂志, 2025, 58(4): 347-351.
[11]	何春霞晋红中. 【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314.
[12]	木葵郭慧文海泉龙海刘昱罗帅寒天黄馨周星雨肖嵘李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327.
[13]	王思凡何春霞晋红中. 【开放获取】药物超敏反应综合征继发肺孢子菌肺炎的临床特征和影响因素探索[J]. 中华皮肤科杂志, 2025, 58(4): 315-321.
[14]	皮江珊陈静思王凌凌沈沾婷罗晓燕王华. 度普利尤单抗治疗6个月至2岁中重度特应性皮炎患儿的前瞻性、单中心临床研究[J]. 中华皮肤科杂志, 2025, 58(10): 930-935.
[15]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.

[开放获取] 中国药疹诊疗指南（2026版）

Chinese guideline for the diagnosis and treatment of drug eruptions （2026 edition）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 92

相关文章 15

Metrics

本文评价

推荐阅读 0